Drug Resistance by using the inhA promoter in clinical isolate for Mycobacterium Tuberculosis cases

Authors

  • Anjali Rana Faculty of Pharmacy, Uttarakhand Technical University, Suddhowala, Dehradun, Uttarakhand
  • Yusra Ahmad Faculty of Pharmacy, Uttarakhand Technical University, Suddhowala, Dehradun, Uttarakhand
  • Narotam Sharma Research Scientist, Molecular Research Laboratory, Department of Biochemistry, SGRRIM&HS, Patel Nagar Dehradun (U.K)
  • Satish Chandra Nautiyal Central Molecular Research Laboratory, Department of Biochemistry, Shri Guru Ram Rai Institute of Medical and Health Sciences, Shri Guru Ram Rai University, Dehradun, Uttarakhand

DOI:

https://doi.org/10.7439/ijbar.v10i12.5205

Keywords:

TB, katG gene, MTB, PCR, Isoniazid, CP

Abstract

Tuberculosis is the most significant infectious disease it is caused by Mycobacterium tuberculosis (MTB). Bacteria that cause tuberculosis can develop resistance to antimicrobial medicines used to cure the disease. There is a multi-drug resistant tuberculosis TB that does not respond to at least Isoniazid and rifampicin, the two most powerful anti-TB drugs.Isoniazid Resistance Tuberculosis (IRTB) in M.tuberculosis is related to loss of catalase and peroxide (CP) activity in TB resistant strains. In other word, INH resistance often happens with the loss and/or decrease of CP or katG activity coded by katG gene. In fact, INH is a prodrug for which cellular activation is required by katG protein, before it

Downloads

Downloads

Published

2019-12-29

Issue

Section

Original Research Articles

How to Cite

Drug Resistance by using the inhA promoter in clinical isolate for Mycobacterium Tuberculosis cases. (2019). International Journal of Biomedical and Advance Research, 10(12), e5205. https://doi.org/10.7439/ijbar.v10i12.5205